Business Context and Reporting Period
This Form 8-K, dated August 1, 2017, reports the completion of a business combination between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Following the merger, the registrant changed its name to Achieve Life Sciences, Inc. and refocused its business on the clinical and commercial development of cytisine, a selective nicotine receptor partial agonist for smoking cessation. The company also executed a 1-for-11 reverse stock split and began trading under the ticker symbol ACHV on the NASDAQ Capital Market on August 3, 2017.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt figures for the combined entity in this report. Financial statements for the acquired business and pro forma information are incorporated by reference from a prior proxy statement.
- Ownership Structure: Post-merger, former OncoGenex equityholders hold approximately 25% of the outstanding capital stock on a fully diluted basis, while former Achieve stockholders hold approximately 75%.
- Exchange Ratio: Each outstanding share of Achieve common stock was converted into the right to receive approximately 359.3053 shares of the Company's common stock (post-split adjusted).
- Stock Split: A 1-for-11 reverse stock split was effected; fractional shares were settled in cash based on the August 1, 2017 closing price.
Material Changes Versus Prior Period
The filing details a fundamental transformation of the registrant's corporate identity and operations:
- Corporate Identity: Name changed from OncoGenex Pharmaceuticals, Inc. to Achieve Life Sciences, Inc.
- Accounting Firm: Ernst & Young LLP was dismissed and PricewaterhouseCoopers LLP (PwC) was appointed as the independent registered public accounting firm effective August 1, 2017.
- Board Composition: Three directors (Neil Clendeninn, Jack Goldstein, David Smith) resigned. Four new directors (Richard Stewart, Anthony Clarke, Donald Joseph, Jay Moyes) were appointed, with Richard Stewart named Chairman.
- Executive Leadership: Scott Cormack resigned as CEO. Richard Stewart was appointed CEO, and Anthony Clarke was appointed President and Chief Scientific Officer.
Management Commentary, Risks, and Unusual Items
Executive Compensation and Severance:
- Scott Cormack (Outgoing CEO): Received a separation package including approximately $1.1 million in salary severance (24 months), $75,000 in bonus severance (12 months), 24 months of health benefits, 100% vesting of outstanding equity awards, and tax return reimbursement.
- New Leadership: Richard Stewart (CEO) receives a $500,000 base salary with a 50% bonus target. Anthony Clarke (President/CSO) receives a $420,000 base salary with a 40% bonus target.
- Continuing Officers: John Bencich (CFO/COO) and Cindy Jacobs (CMO) received retention grants of 54,800 restricted stock units and options for 274,000 shares each, vesting over 36 months.
Stockholder Vote Results: All three proposals submitted at the Special Meeting on August 1, 2017, were approved:
- Merger Approval: 6,411,247 votes for vs. 440,889 against.
- Reverse Stock Split: 15,086,326 votes for vs. 3,383,739 against.
- Name Change: 17,378,452 votes for vs. 1,078,585 against.
Risks/Contingencies: The filing notes that stock options granted to continuing officers will automatically terminate if the new 2017 Equity Incentive Plan is not approved by stockholders within one year of adoption.
Investor Verification Checklist
- Verify the pro forma financial statements and unaudited financials of Achieve Life Science, Inc. referenced in the June 13, 2017 proxy statement.
- Confirm the trading status and volume of the new ticker symbol ACHV on the NASDAQ Capital Market.
- Review the full Separation and Release Agreement (Exhibit 10.1) to understand the total liability associated with the outgoing CEO's departure.
- Monitor the approval status of the 2017 Equity Incentive Plan to ensure retention grants for continuing officers remain valid.
- Assess the clinical development timeline and regulatory status of the company's primary asset, cytisine.